14 - 16 September 2026
Bled, Slovenia
MSS2026 Speakers
Dan Peer
Laboratory of Precision Nanomedicine, Tel Aviv University, Israel
The RNA revolution: from novel vaccines to therapeutic genome editing
Stefano Menegatti
North Carolina State University, USA
Affinity and mixed-mode convective adsorbents for the purification and enrichment of vectors for cell and gene therapies
Andre Germishuizen
National Bioproducts Institute (NBI), South Africa
Commercial scale evaluation of a mixed mode CIMmultus® monolithic column in the production of human immunoglobulin products
Christy Franco
VGXI, USA
Commercial-ready plasmid manufacturing: scaling late-stage cell & gene therapy with regulatory confidence
Jacek Lubelski
NanoCell, Netherlands
tLNP as a novel gene therapy vector to deliver DNA – are we there yet?
Manuela Bartolini
University of Bologna, Italy
Monolith-based immobilized enzyme reactors: enabling technologies for diverse and evolving landscapes
Thomas Muster
BlueSky Immunotherapies, Austria
delNS - an interferon inducing viral vector to tackle head & neck cancer
Yijun Zhou
National Institutes of Health (NIH), USA
Monitoring mRNA vaccine process development using PATfix HPLC
Aleš Štrancar
Sartorius BIA Separations, Slovenia
Away from Cohn, away from EtOH, the next generation plasma fractionation process
be part of mss2026
register
MSS2026 will be Bridging Science and Innovation in Bioprocessing and Biopharma. Are you with us?
mss2024 overview
Get some insight about our past events and hear the testimonials of our past attendees.
Previous event highlights
Highlights